Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD

References

• AdamsSGMeloJLutherM2000A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPDChest11713455210807821
   PubMed Web of Science ®Google Scholar
• ALAT Work Group2004Update to the Latin American Thoracic Society (ALAT) recommendations on infectious exacerbation of COPDArch Bronconeumol403152515225518
   PubMed Web of Science ®Google Scholar
• BallPStahlmannRKubinR2004Safety profile of oral and intravenous Moxifloxacin: Cumulative data from clinical trials and postmarketing studiesClin Ther269405015336463
   PubMed Web of Science ®Google Scholar
• BalterMSLa ForgeJLowDE2003Canadian guidelines for the management of acute exacerbations of chronic bronchitisCan Respir J10Suppl B3B32B
   PubMedGoogle Scholar
• BlondeauJ1999A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolonesJ Antimocrob Chemother43111
   PubMed Web of Science ®Google Scholar
• CerveriIAccordiniSVerlatoG2001Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adultsEur Respir J18859211510810
   PubMed Web of Science ®Google Scholar
• ChodoshSDeabateCAHaverstockD2000Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study GroupRespir Med94182710714475
   PubMed Web of Science ®Google Scholar
• ChodoshSSchreursASiamiG1998The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitisClin Infect Dis2773089798025
   PubMed Web of Science ®Google Scholar
• ChodoshS2005Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitisChest1272231615947342
   PubMed Web of Science ®Google Scholar
• DavidsonRCavalcantiRBruntonJl2002Resistance to levofloxacin and failure of treatment of pneumococcal penumoniaN Engl J Med3467475011882730
   PubMed Web of Science ®Google Scholar
• DalhoffAShalitI2003Immunomodulaotry effects of quinolonesLancet Infect Dis33597112781508
   PubMed Web of Science ®Google Scholar
• DeabateCAMathewCPWarnerJH2000The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitisRespir Med9410293711127487
   PubMed Web of Science ®Google Scholar
• De BenedettoFSevieriG2006Chronic obstructive pulmonary disease (COPD) exacerbation and inflammation of the respiratory tract: clinical implication, prognostic consequences, and therapeutic strategiesMultidisciplinary Respiratory Medicine13648
   Google Scholar
• De MarcoRAccordiniSCerveriI2004An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stagesThorax59120514760151
   PubMed Web of Science ®Google Scholar
• DewanNARafiqueSKanwarB2000Acute exacerbation of COPD. Factors associated with poor outcomeChest1176627110712989
   PubMed Web of Science ®Google Scholar
• EllerJEdeASchabergT1998Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung functionChest113154289631791
   PubMed Web of Science ®Google Scholar
• ForrestANixDEBallowCH1993Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrob Agents Chemother371073818517694
   PubMed Web of Science ®Google Scholar
• GrassiCCasaliLCurtiE2002Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB)J Chemother1459760812583552
   PubMed Web of Science ®Google Scholar
• HallsGA1993The management of infections and antibiotic therapy: a European surveyJ Antimicrob Chemother3198510008360135
   PubMed Web of Science ®Google Scholar
• HautamakiDBruyaTKureishiA2001Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitisToday’s Therapeutic Trends1911736
   Google Scholar
• HuchonGJVergnenègreANeukirchF2002Chronic bronchitis among French adults: high prevalence and underdiagnosisEur Respir J208061212412668
   PubMed Web of Science ®Google Scholar
• KrasemannCMeyerJTillotsonG2001Evaluation of the clinical microbiology profile of moxifloxacinClin Infect Dis32Suppl 1S516311249830
   PubMed Web of Science ®Google Scholar
• KreisSRHerreraNGolzarN2000A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitisJ Clin Outcomes Manag7337
   Google Scholar
• LandenHMöllerMTillotsonGS2001Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacinJ Int Med Res29516011393349
   PubMed Web of Science ®Google Scholar
• ListerPDSandersCC2001Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniaeJ Antimicrob Chemother478111811389113
   PubMed Web of Science ®Google Scholar
• LlorCNaberanKCotsJM2004Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in Primary care centersInt J Clin Pract589374415587773
   PubMed Web of Science ®Google Scholar
• LoddenkemperR2003The European Lung White BookEuropean Respiratory Society
   Google Scholar
• LodeHEllerJLinnhoffA2004Levofloxacin versus clarithromycin in COPD exacerbation: focus on infection-free intervalEur Respir J249475315572537
   PubMed Web of Science ®Google Scholar
• LorenzJBuschWThate-WaschkeI-M2001Moxifloxacin in acute exacerbations of chronic bronchitis:clinical evaluation and assessment by patientsJ Int Med Res29617311393350
   PubMed Web of Science ®Google Scholar
• MacfarlaneJHolmesWGardP2001Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the communityThorax561091411209098
   PubMed Web of Science ®Google Scholar
• MiravitllesM2000Moxifloxacin: an antibiotic designed for use in the communityEur Respir Rev101619
   Google Scholar
• MiravitllesM2002aEpidemiology of chronic obstructive pulmonary disease exacerbationsClin Pulm Med9191197
   Google Scholar
• MiravitllesM2002bExacerbations of chronic obstructive pulmonary disease: when are bacteria important?Eur Respir J20Suppl 369s19s
   Web of Science ®Google Scholar
• MiravitllesM2005Moxifloxacin in respiratory tract infectionsExpert Opin Pharmacother628329315757424
   PubMed Web of Science ®Google Scholar
• MiravitllesMAnzuetoALegnaniD2007bPatient’s perception of exacerbations of COPD – the PERCEIVE studyRespir Med1014536016938447
   PubMed Web of Science ®Google Scholar
• MiravitllesMEspinosaCFernández-LasoE1999Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPDChest11640610424501
   PubMed Web of Science ®Google Scholar
• MiravitllesMFerrerMPontA2004afor the IMPAC study group:Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up studyThorax593879515115864
   PubMed Web of Science ®Google Scholar
• MiravitllesMGuerreroTMayordomoC2000Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysisRespiration6749550111070451
   PubMed Web of Science ®Google Scholar
• MiravitllesMLlorCNaberanK2004bThe effect of various anti-microbial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Primary CareClin Drug Invest246372
   Web of Science ®Google Scholar
• MiravitllesMLlorCNaberanK2005Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary diseaseRespir Med999556515950136
   PubMed Web of Science ®Google Scholar
• MiravitllesMMartín GraczykA2006Tratamiento del paciente con EPOC agudizada. Guía de buena práctica clínica en Geriatría “Enfermedad Pulmonar Obstructiva Crónica”. Normativa conjunta SEPAR-SEGG (Sociedad Española de Geriatría y Gerontología)Ed Elsevier Farma7588
   Google Scholar
• MiravitllesMMolinaJBrosaM2007aClinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysisArch Bronconeumol431621
   PubMed Web of Science ®Google Scholar
• MiravitllesMMurioCGuerreroT2001aFactors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the communityEur Respir J179283311488328
   PubMed Web of Science ®Google Scholar
• MiravitllesMMurioCGuerreroT2002Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPDChest12114495512006427
   PubMed Web of Science ®Google Scholar
• MiravitllesMMurioCGuerreroT2003aCosts of chronic bronchitis and COPD. A one year follow-up studyChest1237849112628879
   PubMed Web of Science ®Google Scholar
• MiravitllesMRosFCobosA2001bThe efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experienceInt J Clin Pract554374411594251
   PubMed Web of Science ®Google Scholar
• MiravitllesMTorresA2004aNo more equivalence trials for antibiotics in exacerbations of COPD, pleaseChest1258111315006934
   PubMed Web of Science ®Google Scholar
• MiravitllesMTorresA2004bAntibiotics in exacerbations of COPD: lessons from the pastEur Respir J24896715572528
   PubMed Web of Science ®Google Scholar
• MiravitllesMZalacainRMurioC2003bSpeed of recovery from acute exacerbations of COPD after treatment with antimicrobials: Results of a two-year studyClin Drug Invest2343950
   PubMed Web of Science ®Google Scholar
• MonsóEGarcía-AymerichJSolerN2003Bacterial infection in exacerbated COPD with changes in sputum characteristicsEpidemiol Infect13179980412948381
   PubMed Web of Science ®Google Scholar
• MurrayCJLLopezAD1997Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease studyLancet34914985049167458
   PubMed Web of Science ®Google Scholar
• NicolsonPAndersonP2000The patient’s burden: physical and psychological effects of acute exacerbations of chronic bronchitisJ Antimicrob Chemother45253210719009
   PubMed Web of Science ®Google Scholar
• NiedermanMSAnzuetoASethiS2006Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agentsRespir Med10017819016531032
   PubMed Web of Science ®Google Scholar
• PapiABellettatoCMBraccioniF2006Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med17311142116484677
   PubMed Web of Science ®Google Scholar
• Perez-GorrichoBRipollMFor the PACE Study Group2003Does short-course antibiotic therapy better meet patient expectationsInt J Antimicrob Agents21222812636982
   PubMed Web of Science ®Google Scholar
• PetoRLopezADBorehamJ1992Mortality from tobacco in developed countries: indirect estimation from vital statisticsLancet3391268781349675
   PubMed Web of Science ®Google Scholar
• PrescottELangePVestboJ1995Chronic mucus hypersecretion in COPD and death from pulmonary infectionEur Respir J8133387489800
   PubMed Web of Science ®Google Scholar
• SaravolatzLManzorOCheckC2001Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniaeJ Antimicrob Chemother47875711389122
   PubMed Web of Science ®Google Scholar
• SchabergTBallinIHuchonG2001A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with amoxicillin-clavulanate oral tablets in the treatment of acute exacerbation of chronic bronchitisJ Int Med Res293142811675905
   PubMed Web of Science ®Google Scholar
• ScheldWM2003Maintaining fluoroquinolone efficacy:review of influencing factorsEmerg Infect Dis91912533274
   PubMed Web of Science ®Google Scholar
• SchentagJNixDEForrestA1996AUIC – the universal parameter within the constraint of a reasonable dosing intervalAnn Pharmacother30102488876867
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEA1998Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1571418229603117
   PubMed Web of Science ®Google Scholar
• SethiSEvansNGrantBJ2002New strains of bacteria and exacerbations of chronic obstructive pulmonary diseaseN Engl J Med3474657112181400
   PubMed Web of Science ®Google Scholar
• SmithJARedmanPWoodheadMA1999Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary diseaseEur Respir J13835810362049
   PubMed Web of Science ®Google Scholar
• Sobradillo PenaVMiravitllesMGabrielR2000Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological studyChest118981911035667
   PubMed Web of Science ®Google Scholar
• SomanAHoneybourneDAndrewsJ1999Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopyJ Antimicrob Chemother44835810590288
   PubMed Web of Science ®Google Scholar
• StarakisIGogosCABassarisH2004Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitisInt J Antimicrob Agents231293715013037
   PubMed Web of Science ®Google Scholar
• StassHKubitzaD1999Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in manJ Antimicrob Chemother43Suppl B839010382880
   PubMed Web of Science ®Google Scholar
• StassHKubitzaDSchühlyU2001Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administrationClin Pharmacokinet40Suppl 11911352436
   PubMed Web of Science ®Google Scholar
• StrattonCW2003Dead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistanceEmerg Infect Dis9101612533275
   PubMed Web of Science ®Google Scholar
• SullivanJTWoodruffMLettieriJ1999Pharmacokinetics of a once-daily oral dose of moxifloxacin (BAY 12-8039), a new enantiomerically pure 8-methoxyquinoloneAntimicrob Agents Chemother432793710543767
   PubMed Web of Science ®Google Scholar
• Urueta-RobledoJArizaHJardimJR2006Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American cohortRespir Med10015041116504492
   PubMed Web of Science ®Google Scholar
• WilsonRKubinRBallinI1999Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitisJ Antimicrob Chemother445011310588312
   PubMed Web of Science ®Google Scholar
• WilsonRAllegraLHuchonG2004Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitisChest1259536415006954
   PubMed Web of Science ®Google Scholar
• WilsonRJonesPSchabergT2006Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitisThorax613374216449273
   PubMed Web of Science ®Google Scholar
• WiseR1999A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone and its potential relation to therapeutic efficacyClin Drug Invest1736587
   Web of Science ®Google Scholar
• WoodcockJMAndrewsJMBoswellFJ1997In vitro activity of BAY 12-8039, a new fluoroquinoloneAntimicrob Agents Chemother4110168980763
   PubMed Web of Science ®Google Scholar